What happened with OFIX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Orthofix Medical Inc. supplies products that help surgeons stabilize the spine, replace or supplement bone grafts, and guide surgery, alongside noninvasive devices that support bone healing. Global Spine generates most of its revenue. Its smaller Global Limb Reconstruction business sells fixation devices for correcting deformities, lengthening limbs and treating complex fractures.
Hospitals, surgery centers and other healthcare buyers purchase its products through sales representatives and distributors. Bone Growth Therapies serves mainly the United States, with most of that business’s revenue coming from third-party payors for devices supplied to patients. Hospitals can buy surgical navigation equipment such as 7D FLASH outright or receive systems in exchange for long-term commitments to buy spinal implants or bone-graft products.
Orthofix also earns marketing fees from MTF Biologics for tissues including Virtuos, Trinity Elite and FiberFuse. MTF processes and supplies these tissues and bills care facilities; Orthofix holds exclusive marketing rights within the agreed territories. MTF is the sole supplier for certain grafts, so this business depends on its access to donors and processing capacity.
Sales depend on physicians choosing the products and on insurance coverage and reimbursement. Medical devices generally require regulatory clearance or approval before marketing. Bone-graft products are sold mainly in the United States, partly because some countries restrict U.S. human donor tissue and bovine collagen.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Orthofix Medical Inc.’s results also depend on nonprofit MTF Biologics, its exclusive tissue-marketing partner and sole supplier of certain allografts.
Globus Medical challenges Orthofix Medical Inc. for spine surgeons’ choice of implants, biologics and systems that guide surgery, and also competes in limb reconstruction. Watch adoption of Globus’s surgical navigation systems for a read on the competition facing Orthofix’s image-guided surgery products.
Bioventus Inc. competes with Orthofix Medical Inc. for spending on therapies that help bones heal and bone graft substitutes used in orthopedic and spine care. Its fracture-care and bone graft substitute businesses are the parts to watch, rather than its broader pain-treatment portfolio.
Alphatec Holdings competes with Orthofix Medical Inc. to sell spine surgeons implants, fixation systems and biologics. Watch surgeon adoption of Alphatec’s procedure-specific systems: the company identifies that adoption as a driver of its future growth.
Enovis Corporation competes with Orthofix Medical Inc. in devices that stimulate bone growth and implants used to reconstruct limbs. Watch bone growth stimulators within its Prevention & Recovery business and limb reconstruction products within Reconstructive, where the two companies overlap.
Xtant Medical Holdings competes with Orthofix Medical Inc. through surgical sales agents and distributors selling spinal fixation implants and bone-healing materials, or orthobiologics. Xtant’s spinal fixation and biologics sales are the relevant lines to watch for competition in spinal fusion.
Medtronic competes with Orthofix Medical Inc. for spine-surgery spending on implants, biologics and technology that helps surgeons perform procedures. Its spine-product news is relevant to Orthofix’s competitive position, rather than news from its diabetes business.
Carlsmed, Inc. offers hospitals and ambulatory surgical centers personalized implants placed between vertebrae for fusion, competing with Orthofix Medical Inc.’s stock implants. Watch growth in surgeons using its aprevo implants and use by existing surgeons, the two sources Carlsmed cites for revenue growth.
OrthoPediatrics Corp. competes with Orthofix Medical Inc. for hospitals’ purchases of implants for pediatric deformity correction and limb reconstruction. Watch its pediatric implant offerings designed to protect growth plates and fit children’s anatomy, where its specialization shapes the competition.
SI-BONE, Inc. competes with Orthofix Medical Inc. in fixation implants for spinal fusion, with a focus on the sacroiliac joint and pelvis. Watch its pelvic fixation products used in spinal fusion, the part of its portfolio most directly tied to this overlap.
Stryker competes with Orthofix Medical Inc. in orthopedic products hospitals use for limb reconstruction and fracture management. Its Orthopaedics business is the relevant area to follow, rather than its larger MedSurg and Neurotechnology business.
Smith & Nephew competes with Orthofix Medical Inc. to supply healthcare customers with products used for limb reconstruction. Its limb reconstruction product news is the relevant part of its broad medical-technology portfolio to watch.
OrthoPediatrics Corp. earningsKIDS
OrthoPediatrics’ report will show demand for pediatric deformity and limb-reconstruction implants, which compete with Orthofix’s products in those cases.
Look at sales or growth in the pediatric implant business. Stronger demand would mean OrthoPediatrics is winning more pediatric deformity and limb-reconstruction cases, increasing competition for Orthofix’s limb-reconstruction products; weaker demand would suggest less pressure from this pediatric specialist.
Alphatec Holdings, Inc. earningsATEC
Alphatec’s report will show whether surgeons are adopting its spine systems, a read on its competition with Orthofix for implant and biologics sales.
Look for evidence that surgeons are adopting Alphatec’s systems and whether that adoption supports growth in the relevant business. Rising adoption alongside growth would suggest Alphatec is winning more spine-procedure spending, putting greater competitive pressure on Orthofix’s implants and biologics; weak adoption or growth would suggest less pressure from this rival.
Orthofix Medical Inc. earningsThis company
Orthofix’s report will show whether growth in Bone Growth Therapies can offset weaker sales in Spinal Implants, Biologics and Enabling Technologies—and help narrow the company’s operating loss.
Read Bone Growth Therapies sales alongside sales of Spinal Implants, Biologics and Enabling Technologies, then compare gross margin with the operating loss. Growth in the first group, stability in the second and a narrower loss would show sales gains reaching profitability; weakness in the larger spine-products group or no narrowing loss would show that growth is not yet fixing the earnings problem.
Bioventus Inc. earningsBVS
Bioventus’s report will show demand for its fracture-care therapies and bone graft substitutes, which compete with Orthofix’s bone-growth and biologics businesses.
Focus on sales in fracture care and bone graft substitutes. Growth in both would suggest Bioventus is capturing more spending on bone healing and grafts, increasing competition for Orthofix’s Bone Growth Therapies and biologics; weakness would point to less pressure from this rival.
GLOBUS MEDICAL INC earningsGMED
Globus Medical’s report will show adoption of its surgical navigation systems, a read on its competition with Orthofix in image-guided surgery.
Look for whether navigation-system adoption is supporting growth in the relevant business. Strong adoption and growth would show hospitals and surgeons choosing Globus’s technology, increasing competition for Orthofix’s image-guided surgery products; limited adoption would suggest less pressure in this area.
